Company profile: VisCardia
1.1 - Company Overview
Company description
- Provider of proprietary implantable medical therapy for heart failure using Synchronized Diaphragmatic Stimulation to modulate intrathoracic pressures and augment cardiac hemodynamics. Products include the VisONE Therapy, an Implantable Pulse Generator, sensing and therapy lead electrodes, an external programmer with telemetry wand, and a laparoscopic implant tool for minimally invasive placement.
Products and services
- VisONE Therapy: Implantable synchronized diaphragmatic stimulation system that modulates intrathoracic pressures and augments cardiac hemodynamics to treat heart failure
- Implantable Pulse Generator (IPG): Algorithm-driven electronic component that delivers stimulation therapy, enclosed in a titanium and silicone case and architected to operate with the proprietary implantable therapy
- Sensing and Therapy Lead Electrodes: Bipolar diaphragm-affixed lead assemblies that sense signals and deliver stimulation to the diaphragm for therapy delivery within the implantable cardiac hemodynamics augmentation system
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to VisCardia
Infraredx
HQ: United States
Website
- Description: Provider of catheter-based coronary imaging devices utilizing near-infrared spectroscopy (NIRS) to identify and characterize vulnerable plaque, alongside CME-accredited webinar and educational sessions on polyvascular disease management, intravascular coronary imaging, coronary physiology, patient risk assessment, and imaging-guided interventions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infraredx company profile →
Reflectance Medical
HQ: United States
Website
- Description: Provider of the Mobile CareGuide sensor platform for noninvasive, continuous assessment of patient metabolic status; developing new technology to improve care of critically ill patients and reduce medical costs and deaths associated with conditions resulting in poor tissue perfusion and acidosis; its noninvasive CareGuide patient monitor continuously and quantitatively displays levels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reflectance Medical company profile →
CV Therapeutics
HQ: United States
Website
- Description: Provider of research-based biopharmaceutical drugs for cardiovascular diseases, particularly angina pectoris, serving the U.S. healthcare industry. The company researches and manufactures cardiovascular drugs and developed Ranexa for chronic angina.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CV Therapeutics company profile →
CardioGenics
HQ: Turkey
Website
- Description: Provider of sensitive diagnostic test products to the IVD market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CardioGenics company profile →
Exithera Pharmaceuticals
HQ: United States
Website
- Description: Provider of antithrombotic and stroke prevention drug development, offering novel, potent, selective small-molecule Factor XIa inhibitors, including frunexian to prevent thrombosis without increased bleeding risk, and EP-7041 evaluated in a Phase 2 trial to prevent thrombosis in COVID-19 ICU patients and investigated to inhibit ECMO-related thrombosis while minimizing bleeding risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exithera Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for VisCardia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to VisCardia
2.2 - Growth funds investing in similar companies to VisCardia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for VisCardia
4.2 - Public trading comparable groups for VisCardia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →